Human Papillomavirus (HPV) News and Research

Latest Human Papillomavirus (HPV) News and Research

Prevalence of oral HPV infection more common among men: Study

Oral HPV infection is more common among men than women, explaining why men are more prone than women to develop an HPV related head and neck cancer, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

27 Jan 2012

Guided Therapeutics seeks CE Mark approval for LuViva Advanced Cervical Scan

Guided Therapeutics, Inc. today announced that it has submitted the application for CE Mark approval for LuViva Advanced Cervical Scan. The CE Mark is required to market LuViva in the 27 nations that comprise the European Union (EU).

23 Jan 2012

Matted lymph nodes may predict throat cancer metastasis

Researchers at the University of Michigan Health System have found a new indicator that may predict which patients with a common type of throat cancer are most likely have the cancer spread to other parts of their bodies.

17 Jan 2012

Office-based medical practice can promote vaccination in adults

Promoting immunizations as a part of routine office-based medical practice is needed to improve adult vaccination rates, a highly effective way to curb the spread of diseases across communities, prevent needless illness and deaths, and lower health care costs, according to a new RAND Corporation study.

12 Jan 2012

SonoPhoto Dynamic Therapy shows promise against squamous cell carcinoma

George Miller developed an ulcer on his bottom lip that began to bleed. His doctor sent cell scrapings to a pathologist, and diagnosed Miller with squamous cell carcinoma (SCC). According to TMD Limited, a medical tourism company, squamous cell carcinoma is the 2nd most common cancer in humans and other animals.

6 Jan 2012

ACS report shows decline in overall cancer death rates

The American Cancer Society's annual cancer statistics report shows that between 2004 and 2008, overall cancer incidence rates declined by 0.6% per year in men and were stable in women, while cancer death rates decreased by 1.8% per year in men and by 1.6% per year in women.

5 Jan 2012

HPV vaccine support by GAVI example of 'equity in health'

Noting that human papillomavirus (HPV) causes 70 percent of cervical cancer cases worldwide, Mary Robinson, former president of Ireland and former GAVI Alliance Board chair, writes in this BMJ Group Blogs post that the GAVI Alliance's decision to support the introduction of HPV vaccine among women in developing countries "is an important example of how we must continue to strive for equity in health. And it will help ensure that the world's less-privileged women remain the strength behind their children, their families, and their communities."

22 Dec 2011

Gardasil – cervical cancer vaccine offered to all boys as well

Soon all adolescent boys may be vaccinated against the sexually transmitted disease that causes some forms of cancer under an extension of a scheme now available to girls, the Australian government's expert panel has recommended. The committee adds that the shots would also widen immunity to the virus, which would further reduce the risk to women and stem the spread of genital warts in both sexes.

19 Dec 2011

HPV test outshines Pap smears for detection of early cervical cancers

A new trial involving nearly 40,000 women in the Netherlands showed that testing for the human papillomavirus, or HPV allowed doctors to detect abnormal cervical cells earlier and prevent more cases of cervical cancer than administering pap smears alone.

18 Dec 2011

Hologic receives FDA approval for Cervista HTA system to detect cervical cancer

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today that the U.S. Food and Drug Administration (FDA) has approved its Cervista HTA (high throughput automation) system for use with the Company's previously approved Cervista human papillomavirus (HPV) HR test.

From Hologic, Inc. 16 Dec 2011

Polarized filter may improve ability to detect precancerous changes, reduce unnecessary biopsies

The same filtered light that enables sunglasses to reduce glare may improve a physician's ability to detect early signs of cervical cancer, reducing unnecessary biopsies and surgery.

30 Nov 2011

Mass immunization with cervical cancer vaccine switched to a more effective variety

Cervarix is currently offered to girls aged 12 and 13 years to protect against strains of the sexually transmitted human papillomavirus (HPV), which causes most cases of cancer of the cervix, the neck of the womb. Cervarix was picked by the Labour government for the first four-year phase of the NHS programme in 2008 because it offered ‘best overall value’ and more than five million doses have been given.

27 Nov 2011

University of Rochester receives U.S. patent for HPV vaccine research

The University of Rochester has been awarded a U.S. patent for research essential to both human papillomavirus vaccines on the market.

23 Nov 2011

Large-scale trials show HPV vaccine effective against multiple strains, could reduce need for screening

"Using GlaxoSmithKline's Cervarix vaccine to protect girls against the human papillomavirus (HPV) that causes cervical cancer is so effective that health authorities could reduce the need for later cervical screening," according to two studies published Wednesday in the journal Lancet Oncology, Reuters reports.

9 Nov 2011

Viewpoints: Super committee clock is ticking; replacing CLASS; 'personhood' amendment in Miss.

There are only three weeks left for the Congressional supercommittee to come up with a plan to reduce the federal deficit by at least $1.2 trillion, and there is no sign that the panel is anywhere close to reaching an agreement. Only one side, in fact, seems to be trying -; the Democrats -; and it is being far too accommodating, given the fierce obstructionism of the other side, the Republicans.

2 Nov 2011

Gen-Probe receives FDA approval for APTIMA HPV assay

Gen-Probe Incorporated announced today that the US Food and Drug Administration (FDA) has approved its APTIMA HPV assay, an amplified nucleic acid test that detects high-risk strains of human papillomavirus (HPV) that are associated with cervical cancer and precancerous lesions.

31 Oct 2011

Fierce Vaccines highlights Inovio's VGX-3100 as one of 10 Promising Therapeutic Vaccines

Inovio Pharmaceuticals, Inc., which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that VGX-3100, its investigational SynCon vaccine for treating cervical dysplasia and cancer caused by human papillomavirus, was highlighted by Fierce Vaccines as one of 10 Promising Therapeutic Vaccines.

31 Oct 2011

Merck third quarter global sales increase 8% to $12.0 billion

Merck, known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2011.

29 Oct 2011

Routine HPV vaccine for boys advised by health advisory panel

A government advisory panel on Tuesday decided that the vaccine against cervical cancer causing virus – HPV (Human Papilloma Virus) should also be given to boys, in part to help prevent the cancer-causing virus through sex. The HPV virus has been recommended for girls aged 9 to 26 since 2006.

26 Oct 2011

Your medical privacy – Another Obamacare casualty

It was a sad day recently when a married menopausal woman learned that her recent Pap test was positive for human papilloma virus (HPV). “How could this happen?” she asked. “I have not had relations with anyone but my husband since we married 30 years ago.”

24 Oct 2011